Tepezza Lawsuit Update 2026: Payouts, Deadlines Guide

The Tepezza lawsuit update for 2026 brings major developments for thousands of plaintiffs. Bellwether trials are moving forward. Settlement talks are heating up. And the window to file a claim is narrowing.

Tepezza, a drug used to treat thyroid eye disease, has been linked to permanent hearing loss and tinnitus. Over 1,000 lawsuits are now consolidated in a federal MDL in Illinois. The stakes are enormous for both patients and Amgen, the company that inherited this mess.

This article covers everything you need to know right now. You will find payout estimates, eligibility rules, filing deadlines, MDL status, tax impacts, and more. One detail that surprises most people: some plaintiffs may be looking at six-figure payouts depending on injury severity.

If you used Tepezza and your hearing changed, keep reading. The information below could directly affect your finances.

Tepezza Lawsuit Update 2026

The Tepezza lawsuit entered a critical phase in 2026. Bellwether trial selections are underway. Discovery is largely complete for the initial batch of cases. Settlement discussions between plaintiffs’ attorneys and Amgen have intensified.

Judge Thomas M. Durkin continues to oversee MDL No. 3079 in the Northern District of Illinois. His rulings in late 2025 and early 2026 shaped the scope of evidence that plaintiffs can present at trial. Key expert testimony regarding ototoxicity has been admitted.

The MDL now includes well over 1,000 individual cases. New filings continue to arrive monthly. Plaintiffs allege that Horizon Therapeutics, the original manufacturer, knew about hearing risks and failed to warn patients or doctors adequately.

Amgen acquired Horizon Therapeutics in October 2023 for $27.8 billion. That purchase price tells you something about the financial resources available on the defense side. It also tells you that settlement capacity exists if negotiations succeed.

The next few months will determine whether individual bellwether trials proceed or a global settlement framework emerges first.

Tepezza Lawsuit Payout

Tepezza lawsuit payouts have not been finalized yet as of early 2026. No global settlement has been reached. But legal analysts and attorneys involved in the litigation have provided estimated ranges based on the injuries alleged.

Payouts will likely vary based on three main factors:

• Severity of hearing loss (partial versus complete, one ear versus both)
• Whether hearing loss is permanent or temporary
• Impact on quality of life (job loss, social isolation, mental health effects)

Attorneys working Tepezza cases have suggested individual payouts could range from $75,000 to over $500,000 for the most serious injuries. Plaintiffs with documented permanent bilateral hearing loss and strong medical records will likely receive higher amounts.

These are not guaranteed figures. They reflect patterns from similar pharmaceutical mass torts. For reference, the 3M earplug litigation saw individual settlements ranging from tens of thousands to over $300,000 depending on injury documentation.

Think of payout estimates like a weather forecast. The closer you get to trial, the more accurate the predictions become. Right now, we’re in the “partly cloudy with a chance of major settlement” stage.

Tepezza Class Action Lawsuit

The Tepezza class action lawsuit is actually not a class action at all. It is a mass tort, specifically a multidistrict litigation. The difference matters for your potential payout.

In a class action, one plaintiff represents a group. Everyone gets the same amount. In a mass tort MDL, each plaintiff has an individual case. Your payout depends on your specific injuries and evidence.

Here is why that distinction matters:

The Tepezza MDL structure means your payout could be much higher than a class action would offer. It also means your medical records and documentation are critical. Stronger evidence means a stronger case.

People often search for “Tepezza class action lawsuit” because that term is more familiar. But knowing it’s a mass tort actually works in your favor. You are not just a name on a list. Your case stands on its own.

Key Takeaway: The Tepezza litigation is a mass tort MDL, not a class action, which means your individual payout depends on your specific injuries and medical evidence.

Tepezza Settlement Amounts

Tepezza settlement amounts in 2026 remain estimated rather than confirmed. No official settlement fund has been established yet. But several data points help frame realistic expectations.

Attorneys on the plaintiffs’ steering committee have suggested a tiered settlement structure is likely. Tiers would be based on the type and severity of auditory injury. Here is what a potential framework could look like:

These tiers are projections, not official numbers. They draw from patterns in similar pharmaceutical product liability cases. The actual settlement structure will depend on bellwether trial outcomes and negotiation results.

One factor that could push amounts higher is the strength of the “failure to warn” evidence. Multiple studies published between 2021 and 2023 documented hearing loss rates between 33% and 81% in Tepezza patients. Plaintiffs argue that Horizon Therapeutics had access to this data and should have warned patients sooner.

Tepezza Lawsuit Eligibility

You may be eligible for the Tepezza lawsuit if you received Tepezza infusions and experienced hearing problems afterward. The core requirement is a documented link between taking the drug and developing auditory side effects.

Here are the general eligibility criteria:

• You received at least one infusion of Tepezza (teprotumumab)
• You developed hearing loss, tinnitus, or other auditory problems during or after treatment
• Your hearing issues were not present before starting Tepezza
• You have medical records documenting the hearing changes
• You have not already signed a release or settlement with the manufacturer

An audiogram taken before and after treatment is one of the strongest pieces of evidence. If your doctor ordered hearing tests that show a measurable decline, that significantly strengthens your case.

Timing matters too. Most plaintiffs experienced symptoms during the standard eight-infusion treatment cycle or within months of completing it. Some reported sudden hearing loss after just two or three infusions.

You do not need to have been diagnosed with total deafness. Even partial hearing loss or persistent ringing qualifies for a claim.

Tepezza Hearing Loss Lawsuit

The Tepezza hearing loss lawsuit centers on one core allegation: the drug causes ototoxicity. Ototoxicity means the drug is toxic to the inner ear, specifically the cochlea and auditory nerve.

Research has backed this claim convincingly. A 2021 study published in the journal Endocrine Practice found that 65% of Tepezza patients reported new hearing problems. A separate 2023 study in Ophthalmology documented hearing loss in 81% of patients in their cohort.

These are staggering numbers. For comparison, most drugs list hearing side effects at rates below 5%. Tepezza’s rates are off the charts.

The FDA initially approved Tepezza in January 2020. At that time, the drug’s label did not include a specific warning about hearing loss. It wasn’t until 2023 that the label was updated to include hearing-related warnings. Plaintiffs argue this delay cost them years of exposure without informed consent.

The type of hearing loss reported is sensorineural. That means it originates in the inner ear or auditory nerve, not the eardrum. Sensorineural hearing loss is often permanent. Hearing aids help some patients, but they don’t restore natural hearing.

Key Takeaway: Multiple peer-reviewed studies found hearing loss rates between 33% and 81% in Tepezza patients, which forms the scientific backbone of these lawsuits.

Tepezza Lawsuit Payout Per Person

The Tepezza lawsuit payout per person will vary significantly based on individual circumstances. There is no flat-rate settlement in mass tort litigation. Each case is evaluated separately.

Several factors determine what a single plaintiff might receive:

• Documented severity of hearing loss (audiogram results before and after treatment)
• Whether hearing loss is temporary or permanent
• Number of Tepezza infusions received
• Impact on daily life (lost wages, need for hearing aids, emotional distress)
• Strength of medical records linking the drug to the injury
• Pre-existing hearing conditions, if any

Based on attorney projections and comparable mass tort outcomes, individual payouts could range as follows:

The “per person” number also depends on attorney fees. Most Tepezza attorneys work on contingency, taking between 33% and 40% of the settlement. That means a $300,000 gross settlement could net you around $180,000 to $200,000 after fees and costs.

Litigation costs, including expert witnesses, medical record retrieval, and court fees, are typically deducted separately from the contingency fee.

Tepezza MDL Update

The Tepezza MDL, designated as MDL No. 3079, is housed in the Northern District of Illinois under Judge Thomas M. Durkin. As of 2026, the litigation is in the bellwether trial preparation phase.

Bellwether trials are test cases. A small number of representative lawsuits go to trial first. The outcomes help both sides gauge the strength of their positions. These results often push settlement negotiations forward.

Key MDL developments in 2025 and early 2026 include:

• Fact discovery completed for initial bellwether pool
• Expert witness reports submitted by both sides
• Daubert motions filed to challenge expert testimony
• Plaintiff profile forms collected from hundreds of claimants
• Case management orders setting bellwether trial schedule

The bellwether selection process narrows hundreds of cases down to a handful. Typically, each side picks cases they believe are strongest for their position. The court then selects the final trial cases from that pool.

If bellwether trials result in plaintiff verdicts, Amgen faces enormous pressure to settle the entire MDL. If the defense wins, settlement values drop. That is why this phase is so significant.

The MDL structure also means that your individual case sits in a queue. It won’t go to trial individually unless bellwether trials fail to produce a settlement framework. Most mass tort MDLs resolve through negotiated settlements after bellwether outcomes.

How to File a Tepezza Lawsuit

Filing a Tepezza lawsuit starts with contacting an attorney who handles pharmaceutical mass tort cases. You do not file the case yourself. Your attorney handles the paperwork, court filings, and negotiations.

Here is the step-by-step process:

• Step 1: Gather your medical records, including Tepezza infusion records and audiograms
• Step 2: Contact a mass tort attorney experienced in pharmaceutical litigation
• Step 3: Complete an initial case evaluation (usually free and confidential)
• Step 4: Sign a retainer agreement (contingency basis, so no upfront cost)
• Step 5: Your attorney files a complaint and submits your case to the MDL
• Step 6: Complete a plaintiff fact sheet with details about your treatment and injuries
• Step 7: Provide additional medical documentation as requested
• Step 8: Wait for bellwether outcomes and settlement negotiations

The entire filing process can take as little as a few weeks once you have your records ready. Getting your hands on medical records is often the slowest part. Request them from your doctor and the infusion center where you received treatment.

Most attorneys offer free consultations. They can tell you quickly whether your case has merit. You pay nothing unless you receive a settlement or verdict.

Key Takeaway: Filing a Tepezza lawsuit costs nothing upfront because attorneys work on contingency, and the process starts with gathering your medical records and infusion history.

Tepezza Lawsuit Filing Deadline

The Tepezza lawsuit filing deadline depends on your state’s statute of limitations for personal injury or product liability claims. There is no single national deadline. Each state sets its own rules.

Most states allow two to three years from the date you discovered or should have discovered the injury. This is called the “discovery rule.” It means the clock starts when you first learned that Tepezza caused your hearing loss, not necessarily when you took the drug.

Some states have shorter windows. Others have exceptions that can extend the deadline. If you are unsure about your state, check with an attorney sooner rather than later.

Here is the critical point: waiting too long can permanently bar your claim. Even if you have a strong case with clear medical evidence, missing the statute of limitations means the court will dismiss it. No exceptions. No extensions.

If you received Tepezza between 2020 and 2024 and have not filed, 2026 may be your last realistic opportunity in many states. Do not assume you have more time.

Tepezza Class Action Settlement

A formal Tepezza class action settlement does not exist in 2026. That phrasing is a bit misleading because the case is an MDL, not a class action. But the concept people are searching for is whether a large-scale settlement deal has been reached. The answer is not yet.

Settlement negotiations are ongoing. Both sides have strong incentives to reach a deal. For Amgen, a global settlement avoids the risk of massive jury verdicts across thousands of individual cases. For plaintiffs, a settlement provides faster compensation without years of additional litigation.

Several signs suggest a settlement could materialize in 2026 or early 2027:

• Bellwether trials are approaching, which historically accelerates negotiations
• The scientific evidence supporting plaintiffs is strong and well-documented
• Amgen has the financial resources to fund a large settlement (2024 revenue exceeded $33 billion)
• Similar pharmaceutical MDLs have settled after bellwether trials begin

When a settlement is reached, it will likely include a claims process administered by a third-party settlement administrator. Claimants will submit proof of Tepezza use, medical records documenting hearing injuries, and a claim form. Payouts would follow a tiered structure based on injury severity.

There is no way to predict the exact timing. But the pieces are moving in the right direction.

Tepezza Tinnitus Lawsuit

The Tepezza tinnitus lawsuit covers patients who developed persistent ringing, buzzing, or hissing in their ears after receiving Tepezza infusions. Tinnitus is one of the most commonly reported side effects in Tepezza clinical and post-market data.

Tinnitus can range from mildly annoying to completely debilitating. Some patients describe a constant high-pitched ringing that never stops. Others experience intermittent episodes that disrupt sleep, concentration, and daily functioning.

Research published in medical journals has documented tinnitus rates between 33% and 67% among Tepezza patients. Those numbers are extraordinary for any medication.

If you developed tinnitus during or after Tepezza treatment, your case may qualify for the MDL even if you did not experience measurable hearing loss. Tinnitus alone represents a compensable injury in product liability law.

The strength of a tinnitus-only claim depends on:

• Medical documentation of when symptoms started
• Connection to Tepezza treatment timeline
• Impact on your life (sleep disruption, anxiety, depression, inability to work)
• Audiological testing showing any associated hearing changes

Tinnitus cases will likely fall into the lower settlement tiers. But “lower tier” does not mean insignificant. Even mild persistent tinnitus claims could result in payouts of $25,000 to $100,000 based on projections from similar pharmaceutical cases.

Key Takeaway: Tinnitus alone qualifies as a compensable injury in the Tepezza litigation, with reported rates between 33% and 67% among patients who took the drug.

Tepezza Side Effects Lawsuit

The Tepezza side effects lawsuit encompasses all adverse reactions linked to the drug, though hearing-related injuries drive the vast majority of claims. Teprotumumab, the active ingredient, is a monoclonal antibody that blocks insulin-like growth factor 1 receptor (IGF-1R).

Beyond hearing loss and tinnitus, reported side effects include:

• Hyperglycemia (elevated blood sugar, especially dangerous for diabetic patients)
• Muscle spasms and cramps
• Nausea and diarrhea
• Hair loss (alopecia)
• Fatigue
• Infusion site reactions

While these additional side effects cause discomfort, the hearing-related injuries are the primary basis for litigation. The reason is straightforward: hearing loss can be permanent, life-altering, and was allegedly not adequately disclosed.

Plaintiffs argue that Horizon Therapeutics downplayed the severity and frequency of side effects in its marketing materials and prescribing information. The original FDA label mentioned hearing-related symptoms but did not emphasize their severity or permanence.

The updated label in 2023 included stronger warnings. But for patients who received infusions between January 2020 and 2023, that update came too late.

If you experienced any side effects from Tepezza, an attorney can evaluate whether your specific injuries qualify for the MDL. The strongest cases involve hearing loss or tinnitus with clear medical documentation.

Tepezza Lawsuit and Amgen

Amgen became the defendant in Tepezza lawsuits after acquiring Horizon Therapeutics in October 2023 for $27.8 billion. When a company buys another company, it typically inherits both assets and liabilities. That includes pending and future litigation.

This acquisition changed the dynamics of the Tepezza litigation in several ways.

First, Amgen has substantially deeper financial resources than Horizon did as a standalone company. Amgen reported over $33 billion in revenue for 2024. This means the company can afford a large-scale settlement. It also means plaintiffs are not at risk of the defendant going bankrupt before paying claims.

Second, Amgen’s legal strategy has been more aggressive than Horizon’s early approach. Amgen has challenged expert testimony, filed motions to dismiss, and pushed back on discovery requests. This is standard for a large pharmaceutical company protecting a lucrative product.

Third, Tepezza remains a significant revenue generator for Amgen. The drug brought in approximately $1.8 billion in sales in 2023 alone. Amgen has a financial interest in resolving the litigation efficiently to protect the drug’s market position.

This may also interest you — What Is a Civil Lawsuit? The Complete Guide for 2026

The bottom line: Amgen has both the motive and the money to settle these cases. The question is when and for how much.

Tepezza Lawsuit Timeline

The Tepezza lawsuit timeline stretches from the first reported hearing loss cases through the current bellwether trial phase. Here is a chronological breakdown of the major events.

This timeline shows that the litigation has moved relatively quickly compared to other pharmaceutical MDLs. The 3M earplug MDL, for example, took over four years before settlements began. The Tepezza MDL could reach resolution faster because the scientific evidence is exceptionally strong.

Plaintiffs should expect the process to take months, not weeks, from this point. Even after a settlement is announced, the claims process and payout distribution typically take 6 to 18 months to complete.

Key Takeaway: The Tepezza MDL is approaching bellwether trials in 2026, and a global settlement could follow within months of those outcomes.

Tepezza Lawsuit Tax Implications

Tepezza lawsuit tax implications depend on what type of damages your settlement covers. The IRS treats different categories of lawsuit compensation differently. This is where most plaintiffs get confused.

Here is the general breakdown:

For most Tepezza plaintiffs, the bulk of the settlement will be classified as compensation for physical injury (hearing loss). That portion is not taxable under federal law. This is good news.

However, if your settlement includes a component for lost wages, that amount is taxable. Punitive damages, if awarded in a trial verdict rather than a negotiated settlement, are always taxable.

Your attorney can structure the settlement allocation to maximize the non-taxable portion. This is a legitimate and common practice. Make sure the settlement agreement clearly specifies which amounts go toward physical injury compensation.

State tax rules vary. Some states follow the federal exemption. Others have their own rules. Consult a tax professional who understands lawsuit settlement taxation before you receive your payout.

Tepezza Lawsuit Funding Options

Tepezza lawsuit funding is available through pre-settlement lending companies that advance money to plaintiffs while their case is pending. These advances are not traditional loans. They are non-recourse, meaning you only repay if you win your case.

If your Tepezza case is causing financial strain because you can’t work or you’re paying for hearing aids and medical treatments, lawsuit funding can bridge the gap. Here is how it works:

• You apply with a lawsuit funding company
• They review your case with your attorney’s cooperation
• If approved, you receive a cash advance (typically $1,000 to $100,000)
• You use the money for any purpose: bills, rent, medical expenses
• Repayment comes from your settlement. If you lose, you owe nothing

The catch is cost. Lawsuit funding companies charge fees that can be substantial. Rates vary, but annual costs often range from 15% to 40% of the funded amount. On a $10,000 advance, you might owe $13,000 to $15,000 after one year.

Before taking funding, discuss it with your attorney. Some lawyers advise against it if your case is strong and resolution is expected soon. Others recognize that financial pressure is real and funding serves a purpose.

Think of lawsuit funding like a payday loan for your settlement. It solves an immediate problem but costs you money. Weigh the trade-off carefully.

Is There a Tepezza Class Action

There is no traditional class action lawsuit for Tepezza. The litigation is structured as a multidistrict litigation, which is a different legal mechanism. But the practical effect is similar in some ways: cases are grouped together for efficiency.

People often confuse mass torts and class actions because both involve large numbers of plaintiffs suing the same defendant. Here is how they differ in the Tepezza context:

In the Tepezza MDL, each plaintiff files an individual complaint. Your case is evaluated on your own merits. Your medical records, your injury severity, and your treatment history determine your compensation. You are not lumped into a single group receiving identical payouts.

This distinction benefits plaintiffs with serious injuries. In a class action, a patient with permanent bilateral hearing loss would receive the same amount as someone with temporary mild tinnitus. That doesn’t feel fair, and the MDL structure fixes that.

The MDL also allows for individual trials if settlement talks fail. Your attorney represents you specifically, not a class of unnamed people.

If someone tells you to “join the Tepezza class action,” what they really mean is to file an individual case that will be part of the MDL. The terms are used interchangeably in casual conversation, but the legal structure gives you more control and potentially more money.

Key Takeaway: The Tepezza litigation is an MDL, not a class action, which gives individual plaintiffs more control over their cases and potentially higher payouts based on their specific injuries.

Frequently Asked Questions

How much is the average Tepezza lawsuit payout in 2026?

No official payouts have been distributed yet as of early 2026.
Attorney estimates suggest individual payouts could range from $25,000 to $550,000 depending on injury severity.
Permanent hearing loss cases are projected at the higher end of that range.

Who qualifies for the Tepezza lawsuit?

Anyone who received Tepezza infusions and developed hearing loss or tinnitus may qualify.
You need medical records showing auditory symptoms that began during or after treatment.
Pre-existing hearing conditions may complicate eligibility but do not automatically disqualify you.

What is the deadline to file a Tepezza lawsuit?

Deadlines vary by state, with most statutes of limitations set at two to three years from injury discovery.
Many plaintiffs who received Tepezza between 2020 and 2023 are approaching their deadlines in 2026.
Filing sooner rather than later protects your right to compensation.

Is the Tepezza lawsuit a class action or mass tort?

The Tepezza litigation is a mass tort structured as MDL No. 3079, not a class action.
Each plaintiff has an individual case evaluated on its own merits.
This means your payout depends on your specific injuries and evidence, not a flat group amount.

Does Amgen have to pay for Tepezza lawsuits?

Yes, Amgen assumed liability for Tepezza lawsuits when it acquired Horizon Therapeutics in October 2023.
Amgen has the financial resources to fund a large-scale settlement, with annual revenues exceeding $33 billion.
The company is the primary defendant in all pending Tepezza litigation.

The Tepezza litigation is reaching a turning point in 2026. Bellwether trials, settlement negotiations, and filing deadlines are all converging this year. If you took Tepezza and your hearing changed, the time to act is now.

Gather your medical records. Contact a mass tort attorney. Get your case evaluated before the statute of limitations closes the door.

Your hearing matters. Your compensation matters. Don’t let a deadline steal what you’re owed.

Also worth exploring: Frivolous Lawsuit: Complete Guide for 2026 Explained

If you're curious, also see GMC Class Action Lawsuit 2026: Payouts and Deadlines

Here's something related: Google Class Action Lawsuit Sign Up 2026: Full Guide